<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04350801</url>
  </required_header>
  <id_info>
    <org_study_id>Hom-based cognitive monitoring</org_study_id>
    <nct_id>NCT04350801</nct_id>
  </id_info>
  <brief_title>Home-based Cognitive Monitoring in MCI</brief_title>
  <official_title>Usefulness of a Home-based Cognitive Monitoring in Non-demented Patients With High-risk of Dementia: a Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an observational study to confirm usefulness of a home-based cognitive
      monitoring in non-demented patients with high-risk of dementia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We prospectively enroll subjects who were diagnosed as mild cognitive impairment based on
      neuropsychological tests battery, brain MRI, and routine blood labs including thyroid
      function tests, vitamine B12 &amp; folate levels, and syphilis screening to rule out other
      secondary causes of dementia. We undergo peripheral blood-based amyloid beta levels and
      regular home-based cognitive monitoring (every 3 months) to investigate whether
      amyloid-positive MCIs progress rapidly using home-based cognitive monitoring during 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>home-based cognitive monitoring score</measure>
    <time_frame>3 months (at baseline, 3 months from baseline, 6 months from baseline)</time_frame>
    <description>a 3-5 minutes brief cognitive testing (range 0~30, higher score means better outcome) using telephone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hippocampal atrophy grade</measure>
    <time_frame>at baseline</time_frame>
    <description>baseline brain MRI markers for hippocampal atrophy using Scheltens' visual rating scale (range 0~4, higher score means more hippocampal atrophy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of lacunes</measure>
    <time_frame>at baseline</time_frame>
    <description>number of lacunes using manual counting on brain MRI (no limit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of microbleeds</measure>
    <time_frame>at baseline</time_frame>
    <description>number of microbleeds using manual counting on brain MRI (no limit)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>high risk MCI</arm_group_label>
    <description>MCI patients with amyloid beta positive (based on peripheral blood level)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low risk MCI</arm_group_label>
    <description>MCI patients with amyloid beta negative (based on peripheral blood level)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>home-based cognitive monitoring</intervention_name>
    <description>a newly developed home-based cognitive monitoring (about 3-5 minutes per test; total score ranges from 0~30; higher score indicates better cognition)</description>
    <arm_group_label>high risk MCI</arm_group_label>
    <arm_group_label>low risk MCI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        clinically diagnosed mild cognitive impairment according to Petersen's criteria
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  persistent cognitive complaints

          -  aged 50 years old or older

          -  below -1.0 standard deviation in any domain of detailed neuropsychological tests
             battery named SNSB (Seoul neuropsychological screening battery)

          -  no ADL (activities of daily living) limitation

          -  subjects who agreed to participate

        Exclusion Criteria:

          -  dementia patients

          -  other structural brain disorders such as hydrocephalus, hemorrhage, or tumors

          -  other neurological disease such as Huntington's disease, Parkinson's disease, or
             epilepsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YunJeong Hong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uijeongbu St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YunJeong Hong, MD,PhD</last_name>
    <phone>820318203933</phone>
    <email>hyj2009@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uijeongbu St. Mary's hospital</name>
      <address>
        <city>Uijeongbu</city>
        <zip>11765</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YunJeong Hong, MD, PhD</last_name>
      <phone>820318203933</phone>
      <email>hyj2009@hanmail.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>YunJeong Hong, MD</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>mild cognitive impairment</keyword>
  <keyword>blood amyloid beta</keyword>
  <keyword>home-based cognitive monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

